EE203 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States
Abstract
Authors
A. Libanore A. Lee B. Baginska M.A. Chaudhary J. Maervoet S. Ray Y. Yuan